Streetbeat News

Earnings

SOHU

Sohu.com Limited (NASDAQ: SOHU) reported a 22% Y/Y revenue decline to $145.4 million for Q3 2023, with a larger than expected adjusted loss per ADS of 30 cents. Brand advertising and online game revenues fell 14% and 21% Y/Y, respectively. Despite this, the adjusted gross margin improved to 76%. The company has $1.4 billion in cash and equivalents. Monthly active users for PC games rose 3% Y/Y, while mobile games saw a 9% Y/Y decline. The company's 'Twin Engine' strategy focuses on short-form content and live broadcasts. Q4 outlook anticipates further declines in brand advertising and online game revenues, with an adjusted net loss projected between $10 million and $20 million. SOHU shares increased by 5.84% in premarket trading.

Portfolio Pulse from Anusuya Lahiri

November 13, 2023 | 12:28 pm

LPTX

Leap Therapeutics (NASDAQ:LPTX) reported Q3 earnings with an EPS of $-0.51, beating estimates by 12.07% but with no change in revenue from the same period last year. Last quarter's EPS miss was followed by a 5.83% share price increase the next day.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 12:20 pm

BA

DIS

PLUG

QQQ

SPY

U.S. stock futures indicate a lower open on Monday, influenced by Moody's downgrade of the U.S. sovereign rating outlook and anticipation of inflation data and Federal Reserve officials' speeches. Despite last week's gains, with the Nasdaq Composite and S&P 500 ending higher, the Russell 2000 faced selling pressure. Analysts express mixed sentiments, with some seeing resilience in the market and others predicting a tech bull market. Key companies like Plug Power and Walt Disney saw premarket movements, while Boeing rose on news of potential Chinese purchases of its 737 Max aircraft.

Portfolio Pulse from Shanthi Rexaline

November 13, 2023 | 12:15 pm

PASG

Passage Bio (NASDAQ:PASG) reported Q3 earnings with an EPS of $-0.49, missing estimates by 6.52% compared to the expected $-0.46. Revenue remained unchanged from the same period last year. Previously, the company had beaten EPS estimates by $0.04, which led to a 2.04% share price increase the following day.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 12:15 pm

ORTX

Orchard Therapeutics (NASDAQ:ORTX) reported Q3 earnings with an EPS of $-0.15, beating estimates by 80% compared to the expected $-0.75. However, revenue declined by $218 thousand from the same period last year. Following last quarter's earnings beat, the share price increased by 1.72% the next day.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 12:15 pm

GENI

Genius Sports reported Q4 revenue of $126M, slightly below the estimated $126.48M. The company also reported an adjusted EBITDA of $11M for the quarter.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 12:12 pm

ROIV

Roivant Sciences plans to announce further clinical results for its two drugs, 1402 and brepocitinib, in the last quarter of the year.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 12:12 pm

GENI

Genius Sports has increased its FY23 adjusted EBITDA guidance from $52 million to $53 million.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 12:10 pm

CELC

Celcuity Inc. (NASDAQ:CELC) reported a Q3 adjusted EPS loss of $0.78, missing the consensus estimate of $0.68 by 14.71%. This represents a 23.81% increase in losses compared to the $0.63 per share loss in the same quarter of the previous year.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 12:09 pm

GENI

Genius Sports has increased its FY23 group revenue forecast to $412 million, up from the previous estimate of $410 million. This new projection slightly exceeds the consensus estimate of $410.47 million.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 12:08 pm